The historical rank and industry rank for Nabriva Therapeutics's PB Ratio or its related term are showing as below:
During the past 10 years, Nabriva Therapeutics's highest PB Ratio was 5.44. The lowest was 0.17. And the median was 1.56.
NBRVF's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.52 * Ranked among companies with meaningful PB Ratio only.
During the past 12 months, Nabriva Therapeutics's average Book Value Per Share Growth Rate was -137.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -78.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -67.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Nabriva Therapeutics was 70.80% per year. The lowest was -78.90% per year. And the median was -54.90% per year.
Back to Basics: PB Ratio
Nabriva Therapeutics PB Ratio Historical Data
The historical data trend for Nabriva Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's PB Ratio
For the Biotechnology subindustry, Nabriva Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's PB Ratio falls into.
Nabriva Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nabriva Therapeutics (OTCPK:NBRVF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nabriva Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 